Last reviewed · How we verify
Platinum-Based Chemotherapy
Platinum-based chemotherapy drugs form covalent crosslinks with DNA, preventing replication and transcription, thereby inducing cancer cell death.
Platinum-based chemotherapy drugs form covalent crosslinks with DNA, preventing replication and transcription, thereby inducing cancer cell death. Used for Non-small cell lung cancer, Ovarian cancer, Colorectal cancer.
At a glance
| Generic name | Platinum-Based Chemotherapy |
|---|---|
| Also known as | cisplatin, carboplatin, paclitaxel + platinum, docetaxel + platinum, vinorelbine + platinum |
| Sponsor | Genprex, Inc. |
| Drug class | Platinum-based alkylating agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Platinum compounds (such as cisplatin, carboplatin, and oxaliplatin) bind to DNA and form interstrand and intrastrand crosslinks. This DNA damage triggers apoptosis and cell cycle arrest in rapidly dividing cancer cells. These agents are non-cell-cycle-phase-specific and have been foundational cytotoxic chemotherapy drugs for decades across multiple cancer types.
Approved indications
- Non-small cell lung cancer
- Ovarian cancer
- Colorectal cancer
- Gastric cancer
- Head and neck cancer
- Testicular cancer
- Bladder cancer
Common side effects
- Nephrotoxicity
- Ototoxicity
- Peripheral neuropathy
- Myelosuppression (neutropenia, thrombocytopenia)
- Nausea and vomiting
- Anemia
- Allergic reactions
Key clinical trials
- A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) (PHASE2)
- Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers (PHASE3)
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer (PHASE1)
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (PHASE2)
- Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) (PHASE2, PHASE3)
- Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer (PHASE3)
- Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer (PHASE2)
- Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |